Calcitonin

Mechanism

A hormone that lowers blood calcium and slows bone breakdown. The injectable/nasal form (from salmon, which is 50x more potent than human) is FDA-approved for osteoporosis and Paget's disease. Also has unique pain-relieving properties for bone fractures, making it useful after vertebral compression fractures.

Effects

## Detailed Effects — Calcitonin (Salmon Calcitonin) ### Skeletal System — Antiresorptive [Tier 1] - 32-amino acid peptide hormone. Salmon calcitonin (sCT) used therapeutically due to 50x greater potency and longer half-life vs human calcitonin. - Binds calcitonin receptor (CTR, class B GPCR) on osteoclasts → cAMP-mediated cytoskeletal disruption → osteoclast quiescence and detachment from bone surface. - Inhibits bone resorption but is a WEAK antiresorptive compared to bisphosphonates and denosumab. - **PROOF Trial (Chesnut et al., Am J Med 2000, n=1,255)**: 200 IU nasal calcitonin daily x 5 years → 33% reduction in new vertebral fractures (but ONLY the 200 IU group, not 100 IU or 400 IU — puzzling dose-response). No significant non-vertebral fracture reduction. - BMD gains: modest +1-2% lumbar spine. Not clinically meaningful at hip. ### Pain — Analgesic Effects [Tier 1-2] - Unique among bone agents: calcitonin has direct ANALGESIC properties independent of its skeletal effects. - Reduces pain from acute vertebral compression fractures — the primary reason calcitonin is still used despite being a weak antiresorptive. - Mechanism: CNS analgesic effect via serotonergic modulation in periaqueductal gray and descending pain inhibitory pathways. - Pain relief onset: within days. Nasal calcitonin reduces VAS pain scores by 30-50% in acute vertebral fracture pain (multiple RCTs). - Also studied for phantom limb pain, complex regional pain syndrome, and bone metastasis pain. ### Calcium Metabolism [Tier 1] - Lowers serum calcium by inhibiting osteoclast-mediated bone resorption and increasing renal calcium excretion. - FDA-approved for hypercalcemia of malignancy (injectable form) — provides rapid, moderate calcium-lowering effect. - Effect is modest and transient ("escape phenomenon" — tachyphylaxis occurs within 48-72 hours due to CTR downregulation). ### Safety Concern — Cancer Risk [Tier 1] - EMA withdrew nasal calcitonin in 2012 after meta-analysis showed increased cancer incidence (4.1% vs 2.9% with placebo). FDA issued advisory but kept it available. - FDA now recommends calcitonin nasal spray only when alternatives are not suitable, and for shortest duration possible. - Mechanism of possible cancer association unclear — may relate to CTR expression on various cancer cell types.

Practitioner Guide

## Practitioner Guide — Calcitonin ### Current Clinical Role (Narrow Indications) Calcitonin's role has dramatically shrunk. The main remaining indications are: 1. **Acute vertebral fracture pain** — the analgesic effect is the primary reason to use calcitonin today. 2. **Hypercalcemia of malignancy** — as a bridge while waiting for bisphosphonate onset. 3. **Osteoporosis in patients who cannot tolerate or have contraindications to all other agents** — this is now rare. ### Formulations - **Miacalcin/Fortical Nasal Spray**: 200 IU per spray, one spray in one nostril daily (alternate nostrils daily). - **Miacalcin Injectable**: 100 IU/mL for SC or IM injection. Used for hypercalcemia (4 IU/kg SC/IM every 12 hours) or when nasal spray is not available/tolerated. ### Acute Vertebral Fracture Pain Protocol - Start nasal calcitonin 200 IU daily as soon as acute vertebral fracture is diagnosed. - Pain relief typically begins within 2-7 days. - Continue for 4-8 weeks until acute pain resolves. - Then STOP calcitonin and transition to a definitive antiresorptive or anabolic agent for fracture prevention. - This is the single best use of calcitonin in modern practice. ### Practitioner Sequencing Perspective - **Calcitonin is NOT a first-line osteoporosis agent**. It is weak. Always prefer teriparatide, abaloparatide, romosozumab (anabolics), or denosumab, zoledronic acid (potent antiresorptives). - Sequence: use calcitonin for PAIN RELIEF only → transition to a real bone agent for fracture prevention. - If a patient has been on nasal calcitonin long-term for osteoporosis, they should be switched to a more effective agent. - Calcitonin does NOT need a transition period — can start an alternative agent immediately. ### Hypercalcemia of Malignancy Protocol - Calcitonin 4 IU/kg SC or IM every 12 hours. - Onset: 2-4 hours (faster than bisphosphonates which take 2-4 days). - Use as a bridge: calcitonin for immediate effect + zoledronic acid 4 mg IV for sustained effect. - Tachyphylaxis ("escape") occurs at 48-72 hours — calcitonin becomes ineffective. The bisphosphonate should be working by then. ### Storage - Nasal spray: Refrigerate unopened. Once opened, store at room temperature (up to 25°C) and use within 35 days. - Injectable: Refrigerate (2-8°C). Protect from light. ### Monitoring - For pain indication: VAS pain scores at baseline, 1 week, 4 weeks. - For osteoporosis (if still being used): DXA annually. But strongly consider switching. - For hypercalcemia: serum calcium every 6-12 hours during treatment. ### Key Caution - Limit duration of use. EMA cancer signal is a real concern. The FDA label now carries warnings. - Ideal use: short-course for pain (4-8 weeks), then stop.

Dosing Protocols

Contraindications & Cautions

• hard stop — Allergy to salmon or fish products
  Salmon calcitonin (Miacalcin, Fortical) is derived from salmon. Patients with known allergy to salmon or fish proteins may experience anaphylaxis or severe allergic reactions.
  Action: Do not use salmon calcitonin. Consider skin test if allergy status uncertain. Human calcitonin formulations do not carry this risk.
• hard stop — Pregnancy
  Calcitonin has been shown to decrease fetal birth weight in animals. Not recommended during pregnancy.
  Action: Do not use during pregnancy.
• hard stop — Under 18 years of age
  Not for pediatric use outside specialist care.
  Action: Do not provide to individuals under 18.
• caution — Long-term use exceeding 6 months
  The European Medicines Agency (EMA) identified a cancer signal with long-term calcitonin use. Meta-analysis of clinical trials showed a small but statistically significant increase in cancer risk with prolonged nasal calcitonin use. EMA restricted use to short-term treatment only.
  Action: Limit use to 6 months or less per EMA guidance. Use for shortest duration necessary. Monitor for malignancy symptoms. Consider alternative osteoporosis treatments for long-term management.
• monitor — Hypocalcemia
  Calcitonin lowers serum calcium. Patients with pre-existing hypocalcemia may experience dangerous further calcium reduction leading to tetany, cardiac arrhythmias, and seizures.
  Action: Monitor serum calcium levels. Correct hypocalcemia before initiation. Ensure adequate calcium and vitamin D intake.

Evidence

• A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study (PROOF)

  Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D (2000) — American Journal of Medicine — PMID: 10758354

  Salmon calcitonin nasal spray 200 IU daily reduced new vertebral fractures by 33% vs placebo over 5 years (PROOF trial). However, only the 200 IU dose was effective (not 100 or 400 IU), raising dose-response concerns. No significant effect on non-vertebral fractures or hip fractures. High dropout rate (59%) weakened the evidence. Calcitonin remains a second-line osteoporosis treatment.

  moderate

Research Summary

## Research Summary — Calcitonin ### Tier 1: Randomized Controlled Trials - **PROOF Trial (Chesnut et al., Am J Med 2000, n=1,255)**: 200 IU nasal calcitonin daily x 5 years: 33% vertebral fracture reduction. But: high dropout rate (59%), no non-vertebral fracture reduction, irregular dose-response. Weakest fracture data among approved osteoporosis agents. - **Multiple RCTs for vertebral fracture pain**: Consistent 30-50% pain reduction with nasal or injectable calcitonin in acute vertebral compression fractures. Pain relief is the strongest and most consistent clinical finding. - **Hypercalcemia RCTs**: Calcitonin provides rapid (2-4 hour onset) but modest and transient calcium lowering. Tachyphylaxis at 48-72 hours confirmed in multiple studies. ### Tier 2: Systematic Reviews & Meta-Analyses - **EMA Safety Review (2012)**: Meta-analysis of long-term calcitonin trials — increased cancer incidence (4.1% vs 2.9%) with nasal calcitonin. Led to EMA withdrawal of nasal formulation. FDA issued safety communication but maintained approval. - Cochrane Review of calcitonin for osteoporosis: modest benefit, inferior to bisphosphonates, denosumab, and anabolic agents. - Systematic reviews of calcitonin for acute fracture pain: consistent moderate analgesic effect, supporting short-term use. ### Tier 3: Case Reports & Practitioner Protocols - Most practitioners now use calcitonin exclusively for acute vertebral fracture pain management. - Some pain specialists use calcitonin for phantom limb pain and CRPS — small case series with mixed results. - Oncologists use injectable calcitonin as a bridge in hypercalcemia emergencies. ### Gaps - Mechanism of the observed cancer signal is not understood — could be a statistical artifact from multiple comparisons. - No modern head-to-head trials against current standard-of-care bone agents (denosumab, romosozumab). - The analgesic mechanism is poorly characterized despite being clinically well-established. ### Active Trials - Oral calcitonin formulations in development — would improve convenience but face the same efficacy limitations. - Research into calcitonin receptor biology for novel drug targets continues. - No major new clinical programs for salmon calcitonin itself.